Price
No data yet.
Social Signal Score
Analyst Ratings
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Tim Knotnerus
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 62
- Beta
- 1.80
- Country
- BE
Financials
AGMB has only 3 quarterly periods on file — the charts below show the full history available.
Net Income
$-17.40MEBITDA
$-17.62MFree Cash Flow
$-13.18MEPS (diluted)
$-0.36Shares Outstanding (diluted)
48.74M+34.5%Operating Expenses
$17.12MCash & Debt
$116.51MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-62.55M | $-1.28 |
| 2024 | $0.00 | $-46.27M | $-1.26 |
| 2023 | $0.00 | $-11.39M | $-0.31 |
| 2022 | $0.00 | $-8.14M | $-0.22 |
Valuation
AGMBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
152+203.33%Social Signal Score
Mentions (6)
- Newsseekingalpha.com·18d ago·Positive
AgomAb Therapeutics NV (AGMB) Discusses Open-Label Extension Results of Phase IIa STENOVA Study in Fibrosing Crohn's Disease Transcript AgomAb Therapeutics NV (AGMB) Discusses Open-Label Extension Results of Phase IIa STENOVA Study in Fibrosing Crohn's Disease Transcript
View source ↗ - Newsbenzinga.com·18d ago·Negative
Agomab Therapeutics Experimental Drug Delivers Sustained Disease Control in Long-Term Crohn's Disease Trial Agomab Therapeutics NV (NASDAQ:AGMB) reported results from the 48-week open-label extension portion of its Phase 2a STENOVA trial of ontunisertib for fibrostenotic Crohn's disease.
View source ↗ - Newsglobenewswire.com·18d ago·Neutral
Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease -- Favorable safety and tolerability profile maintained through up to 60 weeks of treatment with ontunisertib in Fibrostenosing Crohn's disease (FSCD) patients -- -- Low annualized FSCD-related event rate of 3%, with one endoscopic balloon dilation (EBD) and no surgeries reported over the full treatment period -- -- Radiological assessment shows trend for fibrotic strict
View source ↗ - Newsseekingalpha.com·33d ago·Positive
…n Fibrosis Agomab Therapeutics targets fibrotic strictures in Crohn's disease, aiming to create a new treatment category rather than compete with existing therapies. AGMB's ontunisertib showed promising endoscopic results and safety in Phase 2a, with further validation needed in larger, controlled trials. Strong funding runway through 2029 and disciplined R&D execution support AGMB's ability to advance clinical programs without immediate dilution risk.
View source ↗ - Newsglobenewswire.com·38d ago·Neutral
Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors Agomab announced shareholders approved all resolutions submitted for consideration at the Company's Special and Extraordinary General Shareholders' Meeting
View source ↗ - Newsglobenewswire.com·46d ago·Neutral
Agomab to Participate in Upcoming Investor Conferences Antwerp, Belgium, September 3, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the following upcoming investor conferences: Citi's 2026 Biopharma Back to School Conference. Thursday, September 10, 2026 in New York, NY.
View source ↗
Earnings
Wed, Mar 3(in 4 months)
Consensus estimate $-0.95 per share
Typical surprise -177.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.91 vs $1.18miss
- Thu, Apr 23$-45.69 vs $-0.52miss
- Wed, Feb 25$-0.36 vs $-0.52beat
Estimates and results for AGMB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AGMB officers and directors.
- Bought
- $311k
- Sold
- —
8 trades
0 trades
- Epstein David Rbought
- Epstein David Rbought
- Kemula Pierre Thadee Victorbought
- Kemula Pierre Thadee Victorbought
- Kemula Pierre Thadee Victorbought
- Knotnerus Tim Jasperbought
- Epstein David Rbought
- Knotnerus Tim Jasperbought
4 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AGMB.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.